Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Correspondence:
View responses
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Omuro, A. M.P.
Right arrow Articles by DeAngelis, L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Omuro, A. M.P.
Right arrow Articles by DeAngelis, L. M.
Related Collections
Right arrowRelated Article
NEUROLOGY 2005;64:1625-1627
© 2005 American Academy of Neurology
Brief Communications

Ventriculoperitoneal shunt in patients with leptomeningeal metastasis

Antonio M.P. Omuro, MD, Enrico C. Lallana, MD, Mark H. Bilsky, MD and Lisa M. DeAngelis, MD

From Memorial Sloan-Kettering Cancer Center, New York, NY.

Address correspondence and reprint requests to author: Dr. Lisa M. DeAngelis, Department of Neurology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021; e-mail: deangell{at}mskcc.org

The authors reviewed 37 patients with leptomeningeal metastasis (LM) who required a ventriculoperitoneal shunt (VP shunt) for management of intracranial hypertension. Improvement was seen in 27 (77%) patients; subdural hematoma developed in one and shunt malfunction in three. Median overall survival was 2 months (range 2 days to 3.6 years) after VP shunt placement, but there was no procedure-related mortality. The prognosis of LM remained poor, but VP shunt can be an effective palliative tool when required.

Received November 20, 2004. Accepted in final form January 17, 2005.


Related Article

May 10 Highlights
Neurology 2005 64: 1492-1493. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 The OncologistHome page
M. C. Chamberlain
Neoplastic Meningitis
Oncologist, September 1, 2008; 13(9): 967 - 977.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
M. C. Chamberlain, M. Glantz, L. M. DeAngelis, A. M.P. Omuro, E. C. Lallana, and M. H. Bilsky
Ventriculoperitoneal shunt in patients with leptomeningeal metastasis
Neurology, March 14, 2006; 66(5): 783 - 783.
[Full Text] [PDF]

Correspondence:

Read all Correspondence

Ventriculoperitoneal shunt in patients with leptomeningeal metastasis
Marc C. Chamberlain, MD, FAAN, et al.
Neurology Online, 29 Sep 2005 [Full text]
Reply to Chamberlain et al
Lisa M. DeAngelis, MD, et al.
Neurology Online, 29 Sep 2005 [Full text]

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by AAN Enterprises, Inc.